IVX055
/ ImmVirx
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
March 26, 2025
Novel oncolytic RNA viruses, IVX037 and IVX055, demonstrate potent antitumor activity
(AACR 2025)
- P1 | "The promising preclinical anti-tumor activity of IVX037 and IVX055 against a wide range of human malignancies warrants further clinical evaluation in combination with novel immunotherapy strategies. To this end, IVX037 is currently being investigated in an ongoing Phase 1b combination trial with sintilimab (anti-PD-1) in patients with advanced MSS-CRC, gastroesophageal, and ovarian cancer (NCT05427487). Future plans for IVX055 include evaluation in combination with immune checkpoint therapy in patients with advanced non-small cell lung cancer (NSCLC) bearing metastatic liver disease."
IO biomarker • Oncolytic virus • Bladder Cancer • Colorectal Cancer • Gastric Cancer • Genito-urinary Cancer • Hepatocellular Cancer • Liver Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • MSLN • PD-L1
February 12, 2024
ImmVirX receives $3.77M R&D tax refund for FY23
(ImmVirX Press Release)
- "ImmVirX Pty Limited...has received a $3,771,296 Research and Development (R&D) tax refund as part of the Australian Federal Government’s R&D Tax Incentive programme. This amount is based on the R&D undertaken by ImmVirX in the financial year ended 30 June 2023...The refund received by ImmVirX will contribute to the development of its investigational products IVX037 and IVX055 as well as other discovery programmes. IVX037 is progressing in the clinic with a Phase 1 study which is active across multiple clinical sites in Australia and will progress into an evaluation of IVX037 in combination with an immune checkpoint inhibitor therapy mid-CY24....'this funding will support the continued expansion of our research team in Newcastle and allow us to broaden and accelerate our clinical programme with the goal to eventually develop new therapies for patients with colorectal, gastric, ovarian and liver cancer.'"
Financing • Trial status • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor
1 to 2
Of
2
Go to page
1